ACZ885 for the Treatment of Abdominal Aortic Aneurysm
Stopped early · Phase 2 · Has a placebo group
Conditions studied: Abdominal Aortic Aneurysm (AAA)
In brief
This study was designed to assess the safety, tolerability and efficacy of ACZ885 on aneurysmal growth rate in subjects with abdominal aortic aneurysms (AAA). The purpose of the study was to provide data to enable decisions regarding the further development of ACZ885 for subjects with abdominal aortic aneurysms. The design of this study addressed the primary objective of evaluating the change in aneurysmal size in subjects with AAA as a result of treatment with ACZ885.
Key facts
- Study ID
- NCT02007252
- Run by
- Novartis Pharmaceuticals
- People needed
- 65
- Starts
- 2013-12-01
- Expected to finish
- 2015-10-01
- Last updated by the study team
- 2021-01-05
Who can join
Age: 45 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Novartis Investigative Site — Charlottesville, Virginia, United States
- Novartis Investigative Site — Copenhagen, Denmark
- Novartis Investigative Site — Kolding, Denmark
- Novartis Investigative Site — Odense C, Denmark
- Novartis Investigative Site — Amsterdam, Netherlands
- Novartis Investigative Site — Eindhoven, Netherlands
- Novartis Investigative Site — Örebro, Sweden
- Novartis Investigative Site — Stockholm, Sweden
- Novartis Investigative Site — Manchester, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.